Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 5,990 Shares of Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 5,990 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were bought at an average price of $7.50 per share, for a total transaction of $44,925.00. Following the completion of the purchase, the director owned 18,129,186 shares in the company, valued at approximately $135,968,895. This represents a 0.03% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $9.82 on Friday. The stock’s 50 day moving average price is $12.57 and its 200-day moving average price is $20.04. The company has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.23 and a twelve month high of $41.72. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The firm had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million.

Hedge Funds Weigh In On Burning Rock Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Crcm LP increased its stake in shares of Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after buying an additional 4,290 shares during the period. Prospera Financial Services Inc grew its stake in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Burning Rock Biotech during the 4th quarter valued at $220,000. Institutional investors own 30.03% of the company’s stock.

Analysts Set New Price Targets

BNR has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.